<DOC>
	<DOCNO>NCT00876993</DOCNO>
	<brief_summary>Bevacizumab , irinotecan , temozolomide three agent show promising activity variety central nervous system tumor . No prospective study publish currently progress within major consortium combination drug . Brain tumor second common cause cancer pediatrics lead cause cancer death child . For child High Grade Gliomas relapsed/refractory brain tumor , new agent new combination need . Historical data show newly diagnose high grade glioma 5 year progression free survival 28-42 % . Recurrent malignant glioma median survival 3-9 month . Recurrent medulloblastoma 's 2 year survival 9 % . This study phase I study design provide objective observation toxicity establish maximum tolerated dose combination . In addition , study observe response child relapse refractory central nervous system tumor .</brief_summary>
	<brief_title>Study Irinotecan Bevacizumab With Temozolomide Refractory/Relapsed Central Nervous System ( CNS ) Tumors</brief_title>
	<detailed_description>Bevacizumab dose 10 mg/kg day 1 day 15 28 day course give IV . Irinotecan dose 125 mg/m2 day 1 day 15 28 day course give IV first 3 dose level . If MTD temozolomide reach dose level 3 , dose level 4 escalation irinotecan 150 mg/m2 . For dose level 0 Temozolomide , dose 75 mg/m2/day day 1-5 28 day course give PO . Doses escalate accord standard phase I dose escalation criterion .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Medulloblastomas , highgrade glioma , lowgrade glioma , ependymoma eligible . Other central nervous system tumor may consider treatment discretion investigator . Pathology required unless diffuse intrinsic pontine glioma optic pathway tumor . The patient fail first line therapy consider refractory , relapse , recurrent . Exceptions high grade glioma include brain stem glioma . Age 18 month though age 23 year eligible protocol . The patient may receive agent , combination . Patients eligible received combination bevacizumab IV irinotecan prior therapy . They eligible progressive disease agent . Investigator discretion may also use . Bone marrow recover prior therapy ANC &gt; 1500 platelet &gt; 100,000 . Serum creatinine less institutional upper limit norm . ALT/AST &lt; 3 time normal bilirubin &lt; 1.5 time normal . Neurologic symptoms stable 1 week stable decreasing dos steroid . Patients pregnant breast feed . Patients bleed disorder anticoagulant . Uncontrolled hypertension . Other risk bleed determine individual basis . Patients receive enzyme inducing anticonvulsant . Patients significant cardiac pulmonary dysfunction would compromise patient 's ability tolerate protocol therapy would likely interfere study procedure result . For patient receive bevacizumab , surgical procedure receive bevacizumab within 28 day major procedure , 14 day intermediate procedure 7 day minor procedure . Lumbar puncture placement PICC line consider minor procedure may occur time prior therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>